ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,640.50
4.50 (0.28%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.50 0.28% 1,640.50 1,640.00 1,640.50 1,656.00 1,635.00 1,642.00 5,918,777 16:29:57
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.71 67.54B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,636p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.54 billion. Gsk has a price to earnings ratio (PE ratio) of 13.71.

Gsk Share Discussion Threads

Showing 16151 to 16172 of 33100 messages
Chat Pages: Latest  652  651  650  649  648  647  646  645  644  643  642  641  Older
DateSubjectAuthorDiscuss
03/1/2018
14:33
Yes, and as usual, I intend to buy more GSK with the 19p per share proceeds...... ;0)
tradermichael
03/1/2018
14:22
Yes divi & capital growth, perfect investment here, not surprised investors have twigged!
ny boy
03/1/2018
14:19
Trader
6% dividend while you wait.

montyhedge
03/1/2018
14:15
I'm not excited about 1550p as I have a big block of these at 1732p!

Looking forward to the big divi payout next week, though ..... happy 2018 all ....... ;0)

tradermichael
03/1/2018
13:49
GSK look superb, back to 1550p. New shingle's vac is a blockbuster
montyhedge
03/1/2018
13:46
January 3, 2018

NICE has recommended that the NHS should fund GlaxoSmithKline’s Strimvelis gene therapy for the extremely rare immune deficiency condition known as ‘bubble baby syndrome’.

philanderer
03/1/2018
12:16
Monty,Your Filtered for always being a Pratt !!!
garycook
03/1/2018
12:16
Top Picks 2018: Glaxo Smithkline (GSK)
philanderer
03/1/2018
12:05
$40 target thats a 12.77% upside, but with the 6% dividend 18.77% I'm looking for 24.5% return.
montyhedge
03/1/2018
10:31
Fingers crossed, the US research company said 12.77% rise in shareprice but with 6% dividend making 18.77% for 2018 not to bad. I personally looking for 1475p even better return.Fund managers would kill for that 18.77% return.
montyhedge
03/1/2018
09:17
Woodhawk - agreed I also think Emma Walmsley is doing a far better job than is generally appreciated. The thing she needs to develop is her skill set in dealing with a*sehole analysts
ianood
03/1/2018
09:01
Indeed, you're right, Monty, but it doesn't alter my view - I think GSK is worth more.
woodhawk
03/1/2018
08:59
With 12.77% rise in shareprice forecast and 6% dividend, 18.77% return not to bad for 2018.
montyhedge
03/1/2018
08:56
I think Zack is rather parsimonious, Monty. I'm looking for rather more.
woodhawk
03/1/2018
08:43
BUY from US Zacks Investment Research, saying 12.77% upside in shareprice.
montyhedge
03/1/2018
08:35
I topped up on the last dip so it's well above my ave now :)
gbh2
03/1/2018
08:27
Nice move up this morning.
woodhawk
03/1/2018
08:03
Fair value around 1475p.
montyhedge
02/1/2018
22:39
See above post.
eeza
02/1/2018
22:31
Closing price of ADRs equivalent to about 13.55 and half of that rise was post LSE close. A very strong performance given no news.
polaris
02/1/2018
22:02
The ADRs were up 2% when London shut with GSK down.mostly a rise in the £/$ exchange rate.
dr biotech
02/1/2018
18:55
What a boring and irrelevant topic this board pursues on GSK., more importantly the US ADR’s are up nigh on 4% this evening, that is what should drive the price, not a subject that has been dormant for a quarter of a century. GSK depends on more important research than CJD!
wormhasturned
Chat Pages: Latest  652  651  650  649  648  647  646  645  644  643  642  641  Older

Your Recent History

Delayed Upgrade Clock